ClinicalTrials.gg
CompletedNCT00122317Updated Mar 13, 2018Results posted

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 3 interventional study of eculizumab in Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 40 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
187
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
Largest of 18
187 · median 37
Started
2005
with 1 other
Phase 3
14 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
8 of 18
Alexion Pharmaceuticals, Inc.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one has the largest enrollment, is one of 2 that started in 2005, is one of 14 in phase 3, and was the 4th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.

Read the detailed description

An open-label extension study to evaluate long-term safety of eculizumab in PNH patients who had completed the TRIUMPH (C04-001), SHEPHERD (C04-002), and X03-001 studies.

03

Conditions studied

  • Paroxysmal Hemoglobinuria, Nocturnal

Keywords

  • transfusion dependent
  • paroxysmal nocturnal hemoglobinuria
  • hemolytic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have fully completed the TRIUMPH, SHEPHERD, or X03-001 studies
  • TRIUMPH patients who have discontinued receiving drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures
  • Patient must be willing and able to give written
  • Patient must avoid conception during the trial

Exclusion criteria

Exclusion Criteria:

  • Patients who have terminated early from the SHEPHERD or X03-001 studies
  • Patients who have terminated early from the TRIUMPH study due to an adverse event
  • Female who is pregnant, breast feeding, or intending to conceive during the course of the study
  • Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Eculizumab

    600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks

    Drug: eculizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events

    Time frame: From time of consent to a maximum of 2.5 years of study treatment

Secondary outcomes

  1. Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve

    Time frame: From time of first infusion through 24 months of study treatment

  2. Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline

    The FACIT-Fatigue scale is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

    Time frame: From time of first infusion through 24 months of study treatment

  3. Incidence of Thrombosis After Eculizumab Infusion

    Thrombosis was defined as occurrence of major adverse vascular events

    Time frame: From time of first ever dose through last dose (up to 24 months of study treatment)

07

Results

Posted Jun 5, 2017

Participant flow

Participant flow — Overall Study
MilestoneEculizumab
Started187
Completed176
Not completed11
Withdrew: Death3
Withdrew: Adverse event4
Withdrew: Physician decision2
Withdrew: Patient non-compliance1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events
Time frame:
From time of consent to a maximum of 2.5 years of study treatment
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events
ParticipantsEculizumab
Incidence of Treatment-emergent Adverse Events182
SecondaryHemolysis as Measured by Change From Baseline in LDH Area Under the Curve
Time frame:
From time of first infusion through 24 months of study treatment
Reported as:
Mean · U/L x Day
Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve
U/L x DayEculizumab
Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve-365185.8 ± 210407.1
SecondaryQuality of Life as Measured by FACIT-Fatigue Scale Change From Baseline

The FACIT-Fatigue scale is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

Time frame:
From time of first infusion through 24 months of study treatment
Reported as:
Mean · units on a scale
Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline
units on a scaleEculizumab
Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline9.24 ± 12.42
SecondaryIncidence of Thrombosis After Eculizumab Infusion

Thrombosis was defined as occurrence of major adverse vascular events

Time frame:
From time of first ever dose through last dose (up to 24 months of study treatment)
Reported as:
Number · Number of events per 100 patient-years
Incidence of Thrombosis After Eculizumab Infusion
Number of events per 100 patient-yearsEculizumab
Prior to first eculizumab dose7.82
From first dose of eculizumab through last dose1.99

Adverse events

Collected over From time of consent to a maximum of 2.5 years of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab3/187 (1.6%)57/187 (30.5%)180/187 (96.3%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventEculizumab
HaemolysisBlood and lymphatic system disorders5/187
Abdominal painGastrointestinal disorders5/187
PyrexiaGeneral disorders5/187
Paroxysmal Nocturnal HaemoglobinuriaRenal and urinary disorders4/187
AnaemiaBlood and lymphatic system disorders3/187
CholecystitisHepatobiliary disorders3/187
Viral InfectionInfections and infestations3/187
Aplastic anaemiaBlood and lymphatic system disorders2/187
CholelithiasisHepatobiliary disorders2/187
Portal vein thrombosisHepatobiliary disorders2/187
Most frequent other events
Showing 10 of 36
Most frequent other events
EventEculizumab
NasopharyngitisInfections and infestations74/187
HeadacheNervous system disorders61/187
Upper Respiratory Tract InfectionInfections and infestations58/187
DiarrhoeaGastrointestinal disorders44/187
NauseaGastrointestinal disorders39/187
VomitingGastrointestinal disorders38/187
ArthralgiaMusculoskeletal and connective tissue disorders33/187
Back PainMusculoskeletal and connective tissue disorders32/187
Influenza like IllnessGeneral disorders29/187
CoughRespiratory, thoracic and mediastinal disorders29/187

Baseline characteristics

Age, Continuous
Age, Continuous(years)Eculizumab
Mean42.1 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female101
Male86
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eculizumab
Asian6
Black7
Caucasian168
Other6
08

Study locations

40 sites
  • Stanford University Medical Center, Division of Hematology
    Stanford, California 94305, United States
  • Hartford Hospital, Cancer Clinical Research Office
    Hartford, Connecticut 06102, United States
  • Cleveland Clinic Florida, Department of Clinical Research
    Weston, Florida 33331, United States
  • Indianapolis University Cancer Center
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins University Medical Center
    Baltimore, Maryland 21205, United States
  • National Heart, Lung, and Blood Institute, National Institutes of Health
    Bethesda, Maryland 20892, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mayo Clinic, Divison of Hematology
    Rochester, Minnesota 55902, United States
  • Washington University, Department of Internal Medicine/Division of Hematology
    Saint Louis, Missouri 63110, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10017, United States
  • Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program
    Philadelphia, Pennsylvania 19104, United States
  • Royal North Shore Hospital, Haematology Department
    Saint Leonards, New South Wales 2065, Australia
  • Princess Alexandra Hospital, Oncology Haematology Radiation Department
    Woolloongabba, Queensland 4102, Australia
  • The Queen Elizabeth Hospital, Haematology/Oncology Department
    Woodville South, South Australia 5011, Australia
  • The Royal Perth Hospital, Department of Haematology/Level 2
    Perth, Western Australia 6000, Australia
  • Royal Melbourne Hospital, Department of Clinical Haematology & Medical Oncology
    Parkville, 3050, Australia
  • Ucl St. Luc, Hematology Department
    Brussels, 1200, Belgium
  • University of Alberta, Cross Cancer Institute
    Edmonton, Alberta T6G 2B7, Canada
  • London Regional Cancer Centre, Clinical Research Unit Room C3080
    London, Ontario N6A4L6, Canada
  • Hopital Saint Louis, Centre d'investigation Clinique
    Paris, Cedex 10 75475, France
  • Universitatsklinikum Essen, Zentrum fur Innere Medizin
    Essen, D-45147, Germany
  • Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin
    Hannover, D-30625, Germany
  • Universitatskliniken des Saarlandes, Innere Medizin 1
    Homburg/Saar, D-66421, Germany
  • Institut fur Klinische Transfusionmedizin und Immunogenetik, Abtlg. Transfusionmedizin des Univ. Ulm
    Ulm, D-89081, Germany
  • St. James's Hospital, Cancer Clinical Trial Office
    Dublin, 8, Ireland
  • Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica
    Firenze, 50139, Italy
  • Ospedale San Martino, Department of Hematology
    Genova, I-16132, Italy
  • Ospedale Maggiore di Milano, Divisione di Ematologia
    Milano, 35-20122, Italy
  • Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico
    Napoli, 5-80131, Italy
  • Ospedale San Bortolo, Divisione di Ematologia
    Vicenza, 37-36100, Italy
  • UMC St. Radboud, Department of Hematology
    Nijmegen, GA 6525, Netherlands
  • Hospital Clinic i Provincial, Servicio de Hematologia
    Barcelona, 08036, Spain
  • Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia
    Barcelona, 08916, Spain
  • Hospital De La Paz, Servicio de Hematologia
    Madrid, 28046, Spain
  • Stockholm South Hospital, Division of Hematology
    Stockholm, 118-83, Sweden
  • Leeds General Infirmary, D Floor Brotherton Wing
    Leeds, LS1 3EX, United Kingdom
  • St. George's Hospital, Department of Haematology
    London, SW17OQT, United Kingdom
09

References and documents

Publications

  • Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 Dec 1;110(12):4123-8. doi: 10.1182/blood-2007-06-095646. Epub 2007 Aug 16. PubMed 17702897 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2005 to primary completion in Sep 2008, 40 months.

Results were first posted in Jun 2017, 8 years 9 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 40 months is above that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2005
First posted
Jul 22, 2005
StartActual
May 2005
Primary completionActual
Sep 2008
CompletionActual
Oct 2008
Results first posted
Jun 5, 2017
Last update
Mar 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00122317
Responsible party
Sponsor
First posted
Jul 22, 2005
Start date
May 2005
Primary completion
Sep 2008
Completion
Oct 2008
Results posted
Jun 5, 2017
Last update
Mar 13, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion